Written answers
Tuesday, 14 February 2023
Department of Health
Medicinal Products
Claire Kerrane (Roscommon-Galway, Sinn Fein)
Link to this: Individually | In context | Oireachtas source
594. To ask the Minister for Health the number of cariban prescriptions that have been processed through the drugs payment scheme to date, in tabular form. [6591/23]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
Following the recommendations of the HSE Medicines Management Programme, reimbursement support for Cariban® (doxylamine/pyridoxine) has been made available under an exceptional arrangement on an individual patient basis where consultant initiated.
This exceptional arrangement has been in operation since 1 January 2023 to ensure that those patients suffering from hyperemesis gravidarum have access to Cariban®, an unlicensed Exempt Medicinal Product, which cannot be added to the formal HSE reimbursement list. Hyperemesis gravidarum is expected to affect about 1% of the pregnant population.
As of 10th February 2023, the number of applications received by the Primary Care Reimbursement Service (PCRS) stands at 384. The number of applications to date is in line with expectations.
No comments